OBJECTIVE: To assess the effectiveness of routine sirolimus eluting stent (SES) implantation for unselected patients with in-stent restenosis and to provide preliminary information about the angiographic outcome for lesion subgroups and for different in-stent restenosis patterns. DESIGN: Prospective, single centre registry. SETTING: Tertiary referral centre. PATIENTS: 44 consecutive patients (53 lesions) without previous brachytherapy who were treated with SES for in-stent restenosis were evaluated. Routine angiographic follow up was obtained at six months and the incidence of major adverse cardiovascular events was evaluated. RESULTS: At baseline, 42% of the lesions were focal, 21% diffuse, 26% proliferative, and 11% total occlusions. Small vessel size (reference diameter < or = 2.5 mm) was present in 49%, long lesions (> 20 mm) in 30%, treatment of bypass grafts in 13%, and bifurcation stenting in 18%. At follow up, post-SES restenosis was observed in 14.6%. No restenosis was observed in focal lesions. For more complex lesions, restenosis rates ranged from 20-25%. At the one year follow up, the incidence of death was 0, myocardial infarction 4.7% (n = 2), and target lesion revascularisation 16.3% (n = 7). The target lesion was revascularised because of restenosis in 11.6% (n = 5). CONCLUSIONS: Routine SES implantation is highly effective for focal in-stent restenosis and appears to be a promising strategy for more complex patterns of restenosis.
OBJECTIVE: To assess the effectiveness of routine sirolimus eluting stent (SES) implantation for unselected patients with in-stent restenosis and to provide preliminary information about the angiographic outcome for lesion subgroups and for different in-stent restenosis patterns. DESIGN: Prospective, single centre registry. SETTING: Tertiary referral centre. PATIENTS: 44 consecutive patients (53 lesions) without previous brachytherapy who were treated with SES for in-stent restenosis were evaluated. Routine angiographic follow up was obtained at six months and the incidence of major adverse cardiovascular events was evaluated. RESULTS: At baseline, 42% of the lesions were focal, 21% diffuse, 26% proliferative, and 11% total occlusions. Small vessel size (reference diameter < or = 2.5 mm) was present in 49%, long lesions (> 20 mm) in 30%, treatment of bypass grafts in 13%, and bifurcation stenting in 18%. At follow up, post-SESrestenosis was observed in 14.6%. No restenosis was observed in focal lesions. For more complex lesions, restenosis rates ranged from 20-25%. At the one year follow up, the incidence of death was 0, myocardial infarction 4.7% (n = 2), and target lesion revascularisation 16.3% (n = 7). The target lesion was revascularised because of restenosis in 11.6% (n = 5). CONCLUSIONS: Routine SES implantation is highly effective for focal in-stent restenosis and appears to be a promising strategy for more complex patterns of restenosis.
Authors: R Waksman; R L White; R C Chan; B G Bass; L Geirlach; G S Mintz; L F Satler; R Mehran; P W Serruys; A J Lansky; P Fitzgerald; B Bhargava; K M Kent; A D Pichard; M B Leon Journal: Circulation Date: 2000-05-09 Impact factor: 29.690
Authors: S Giri; S Ito; A J Lansky; R Mehran; J Margolis; P Gilmore; K N Garratt; F Cummins; J Moses; P Rentrop; S Oesterle; J Power; K M Kent; L F Satler; A D Pichard; H Wu; A Greenberg; T A Bucher; W Kerker; A S Abizaid; J Saucedo; M B Leon; J J Popma Journal: Catheter Cardiovasc Interv Date: 2001-01 Impact factor: 2.692
Authors: M Adamian; A Colombo; C Briguori; T Nishida; F Marsico; C Di Mario; R Albiero; I Moussa; J W Moses Journal: J Am Coll Cardiol Date: 2001-09 Impact factor: 24.094
Authors: Juergen vom Dahl; Ulrich Dietz; Philipp K Haager; Sigmund Silber; Luigi Niccoli; Hans Juergen Buettner; Francois Schiele; Martyn Thomas; Philippe Commeau; David R Ramsdale; Eulogio Garcia; Christian W Hamm; Rainer Hoffmann; Thorsten Reineke; Heinrich G Klues Journal: Circulation Date: 2002-02-05 Impact factor: 29.690
Authors: P S Teirstein; V Massullo; S Jani; J J Popma; G S Mintz; R J Russo; R A Schatz; E M Guarneri; S Steuterman; N B Morris; M B Leon; P Tripuraneni Journal: N Engl J Med Date: 1997-06-12 Impact factor: 91.245
Authors: R Mehran; G Dangas; A S Abizaid; G S Mintz; A J Lansky; L F Satler; A D Pichard; K M Kent; G W Stone; M B Leon Journal: Circulation Date: 1999-11-02 Impact factor: 29.690
Authors: F Alfonso; A Cequier; J Zueco; C Morís; C P Suárez; T Colman; E Esplugas; M J Pérez-Vizcayno; C Fernández; C Macaya Journal: Am J Cardiol Date: 2000-02-01 Impact factor: 2.778
Authors: M B Leon; P S Teirstein; J W Moses; P Tripuraneni; A J Lansky; S Jani; S C Wong; D Fish; S Ellis; D R Holmes; D Kerieakes; R E Kuntz Journal: N Engl J Med Date: 2001-01-25 Impact factor: 91.245
Authors: Helge Möllmann; Albrecht Elsässer; Holger Nef; Steffen Schneider; Christoph A Nienaber; Gert Richardt; Michael Weber; Malte Kelm; Benny Levenson; Tassilo Bonzel; Ulrich Tebbe; Georg Sabin; Thomas Pfannebecker; Jochen Senges; Christian W Hamm Journal: Clin Res Cardiol Date: 2008-03-03 Impact factor: 5.460
Authors: Negar Faramarzi; Mojtaba Salarifar; Seyed Ebrahim Kassaian; Ali Mohammad Haji Zeinali; Mohammad Alidoosti; Hamidreza Pourhoseini; Ebrahim Nematipour; Mohammad Reza Mousavi; Hamidreza Goodarzynejad Journal: J Tehran Heart Cent Date: 2013-01-08